ACS Medication Strategy Decision Aid Tool

Clinical calculation support · Verify results before clinical use

Clinical context

Select the patient and treatment factors to generate a structured antithrombotic strategy discussion.

Choose the clinical presentation.

Select the current or planned reperfusion approach.

Select whether a stent was implanted during the index admission.

Examples include atrial fibrillation, venous thromboembolism, or a mechanical valve.

This is a contraindication to prasugrel.

This simplified selection is not a validated bleeding-risk assessment.

Availability can affect practical agent selection.

Clinical context

Antithrombotic therapy after acute coronary syndrome balances prevention of recurrent ischemic events against bleeding. Selection and duration depend on ACS type, whether PCI or fibrinolysis was performed, stent and procedural factors, need for oral anticoagulation, contraindications, and patient-specific bleeding and ischemic risk.

Key decision points

  • For ACS patients without high bleeding risk, aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy.
  • For ACS patients undergoing PCI, ticagrelor or prasugrel is generally preferred to clopidogrel when appropriate.
  • When long-term oral anticoagulation is required after PCI, aspirin is generally discontinued after 1–4 weeks, with continued oral anticoagulation plus a P2Y12 inhibitor, preferably clopidogrel.
  • Prasugrel must not be used in patients with prior stroke or TIA. Age, body weight, contraindications, drug interactions, and bleeding risk also need review.
  • Fibrinolysis pathways differ from primary PCI pathways; follow a dedicated STEMI fibrinolysis protocol and age-specific dosing guidance.

Important limitations

This aid is intentionally simplified and does not capture every factor required for prescribing. It does not calculate a validated bleeding score or assess renal function, age, body weight, prior gastrointestinal bleeding, hemoglobin, platelet count, drug interactions, planned surgery, coronary anatomy, or stent-thrombosis risk.

It does not provide complete loading-dose instructions for each P2Y12 inhibitor or a patient-specific anticoagulant dose. Confirm these details in the relevant guideline, product information, and local protocol before treatment.

Clinical disclaimer: For trained healthcare professionals. This decision aid supports, but does not replace, clinical judgment, current guideline review, local protocols, and shared decision-making. Do not use the illustrative regimen as a standalone prescription.

References

Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151:e771–e862. doi:10.1161/CIR.0000000000001309.

Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720–3826. doi:10.1093/eurheartj/ehad191.